Clinical trials
Respiratory Syncytial Virus (RSV) clinical trials
Below are recruiting respiratory syncytial virus (rsv) clinical trials, each written for real people, not researchers. We’re tracking 38 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06197152Recruiting
RSV severity markers in hospitalized adults
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
CréteilAges 18 years+ - NCT07860216RecruitingPhase 3
RSV vaccine safety and immune response study for older adults
This trial tests an experimental vaccine to protect older adults against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. It looks at whether the vaccine is safe and how well it boosts immunity. If you are healthy and over 60, you might be able to join.
GuiZhou, GuizhouAges 60 years+ - NCT07810010RecruitingPhase 2
Vaccine for RSV and HMPV in adults 60 and older
This study tests a new vaccine that protects against two common respiratory viruses: RSV and HMPV. It aims to see if the vaccine is safe and works well in older adults, who are at higher risk for serious illness from these viruses.
Bruse, Australian Capital TerritoryAges 60 years+ - NCT06521944Recruiting
RSV vaccine safety registry for pregnant people
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
Wilmington, North CarolinaAges 18–50 - NCT07768345RecruitingPhase 3
Revaccination with RSV vaccine for immunocompromised adults
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
Los Angeles, CaliforniaAges 18 years+ - NCT07764237RecruitingPhase 1
mRNA vaccine for older adults to prevent RSV and hMPV
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
Québec, QuebecAges 60 years+ - NCT07734649RecruitingPhase 1/Phase 2
RSV and HMPV vaccine study for adults 60 and older
This study tests a new vaccine that targets two respiratory viruses, RSV and HMPV, to see if it's safe and effective in adults 60 years and older. It may help prevent serious lung infections caused by these viruses.
Gadsden, AlabamaAges 60 years+ - NCT07694557RecruitingPhase 1
Safety and immune response study of YKYY025 RSV vaccine
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Anning, YunnanAges 18 years+ - NCT07658534RecruitingPhase 2/Phase 3
Ziresovir for high-risk adults with RSV
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
Beijing, Beijing MunicipalityAges 18–85 - NCT07653100RecruitingPhase 3
RSV vaccine study for adults with chronic conditions
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Visakhapatnam, Andhra PradeshAges 18 years+ - NCT07582796RecruitingPhase 1/Phase 2
RSV Vaccine Study for Adults in China
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
Zigong, SichuanAges 18 years+ - NCT07578298RecruitingPhase 4
RSV protection for aboriginal infants
This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.
Darwin, Northern TerritoryAges 6 months–9 months - NCT07516418RecruitingPhase 1
RSV and Flu H5 Vaccine Formulations Study
This study tests different versions of experimental vaccines designed to protect against RSV (a common respiratory virus) and flu H5. You'll receive one of these vaccines and be monitored to see how safe it is and how your body responds.
Griffith, QueenslandAges 18–49 - NCT07482657RecruitingPhase 2
Zelicapavir for RSV in infants and toddlers
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
BangkokAges 4 weeks–3 years - NCT06754605RecruitingPhase 1/Phase 2
Testing a new RSV vaccine for safety and immune response
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Langfang, HebeiAges 18–120 - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT06881056Recruiting
Aerosol interferon for RSV pneumonia in toddlers
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
Chengdu, SichuanAges 1–3 - NCT07272434RecruitingPhase 3
RSV vaccine trial for adults 60 and older
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Guangzhou, GuangdongAges 60 years+ - NCT07239583Recruiting
RSV infection and health impact in older adults in Vietnam
This study looks at how common RSV (a virus that can cause serious breathing problems) is in older adults who are hospitalized with respiratory symptoms or worsening heart/lung conditions. By joining, you help researchers understand the virus and improve care for people your age.
Ho Chi Minh City, Southern VietnamAges 60 years+ - NCT07214571RecruitingPhase 2
Study of S-337395 for RSV in high-risk adults
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT07158814RecruitingPhase 4
Testing the safety of an RSV antibody in infants
This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.
Oakland, CaliforniaAges 1 month–7 months - NCT07106918RecruitingEarly Phase 1
SIBP-A16 Injection Safety Study in Healthy Adults
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
WuhanAges 18–45 - NCT07050732RecruitingPhase 2
Testing RSV vaccine in people with weakened immune systems
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
Baltimore, MarylandAges 18 years+ - NCT06998251Recruiting
Immune response to strep pneumonia in older adults
This study looks at how the immune system in the nose and throat reacts to Streptococcus pneumoniae bacteria and viruses in adults aged 60-85. It may help researchers find better ways to prevent or treat pneumonia.
GenevaAges 60–85
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for respiratory syncytial virus (rsv)?
- Yes. Clin2 currently lists 38 recruiting respiratory syncytial virus (rsv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a respiratory syncytial virus (rsv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a respiratory syncytial virus (rsv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.